Is cimepilimab an imported drug or a domestic drug?

Cemiplimab (Cemiplimab) is a monoclonal antibody drug that targets programmed death protein 1 (PD-1). It is mainly used to treat certain types of cancer, such as cutaneous squamous cell carcinoma and basal cell carcinoma (BCC), and certain non-small cell lung cancer (NSCLC). As an immunotherapy, cimepilimab exerts an anti-tumor effect by blocking the PD-1 pathway and enhancing the immune response of T cells to tumor cells.

In the Chinese market, cimepilimab has not yet received marketing approval and is not included in medical insurance. Therefore, patients do not have legal channels to obtain the drug in the country, and there is no clear official information on the price of the drug. However, in the international market, including the United States and Europe, cimepilimab has been launched and put into use. The common specification is 350mg/7mL (50mg/mL). Its price is usually between 40,000 and 100,000 yuan. The specific price will change due to exchange rate fluctuations.

The clinical application of cimepilimab is mainly focused on patients with advanced or metastatic cutaneous squamous cell carcinoma who have failed to respond to previous treatments. Studies have shown that the drug shows good efficacy and tolerability in these patients. In addition, cimepilimab is also being evaluated in multiple clinical trials for its application potential in different types of tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, etc. These research results may provide more basis for future listings in China.

Although cimepilimab has achieved certain results in the international market, no domestic generic drugs have yet entered the market. This also means that Chinese patients still need to wait for more policy support and research and development progress in order to enjoy the treatment opportunities brought by this innovative drug. At present, domestic pharmaceutical companies may be in the research and development stage, hoping to launch corresponding generic drugs as soon as possible to meet market demand and patient treatment needs.

Reference materials:https://www.libtayohcp.com/